MannKind Corporation and One drop have announced a partnership for a study of the Afrezza inhaled Insulin and One Drop’s diabetes platform. 

The hope is to discover a new and simpler way to take insulin. 

Dr. Raymond Urbanski, Chief Medical Officer of MannKind Corporation, said, “This study is intended to evaluate whether combining a solutions-oriented digital disease management platform like One Drop with an innovative drug like Afrezza^® will provide patients with an improved ability to manage their diabetes.”

Click here to read the full release.